Exosomal delivery of TRAIL and miR‑335 for the treatment of hepatocellular carcinoma (Review)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Thapa, N. | - |
dc.contributor.author | Chwae, Y.J. | - |
dc.contributor.author | Yoo, K.H. | - |
dc.contributor.author | Won, T.-B. | - |
dc.contributor.author | Kang, D. | - |
dc.contributor.author | Choi, D. | - |
dc.contributor.author | Kim, J. | - |
dc.date.accessioned | 2024-04-22T05:00:57Z | - |
dc.date.available | 2024-04-22T05:00:57Z | - |
dc.date.issued | 2023-01 | - |
dc.identifier.issn | 1107-3756 | - |
dc.identifier.issn | 1791-244X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/73407 | - |
dc.description.abstract | Liver cancer is the sixth most prevalent type of cancer worldwide and accounts for the third most frequent cause of cancer-associated mortality. Conventional anticancer drugs display limited efficacy owing to their short half-life, poor solubility and inefficient drug delivery. Despite advancements being made in drug discovery and development for the treatment of hepatocellular carcinoma (HCC), drug inefficacy and drug continue to pose significant obstacles to effective treatment. Therefore, it is imperative that novel treatment strategies be developed with the aim of developing anticancer treatments without any side-effects and with long-term durability. Extracellular vesicles, such as exosomes, intercellular communication agents which have the ability to carry heterogenous molecules with high penetrability, low immunogenicity and longer durability, may provide a versatile natural delivery system. The present review article illustrates the innovative treatment strategy using exosomes as a delivery agent for two distinct anticancer candidates, i.e., tumor necrosis factor-related apoptosis-inducing ligand and microRNA-335. The aim of the present review was to present a unique strategy for the development of an exceptional anticancer treatment therapy exploiting exosomes as a delivery vehicle which may be used for HCC. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | NLM (Medline) | - |
dc.title | Exosomal delivery of TRAIL and miR‑335 for the treatment of hepatocellular carcinoma (Review) | - |
dc.type | Article | - |
dc.identifier.doi | 10.3892/ijmm.2022.5206 | - |
dc.identifier.bibliographicCitation | International journal of molecular medicine, v.51, no.1 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000899830900001 | - |
dc.identifier.scopusid | 2-s2.0-85142535752 | - |
dc.citation.number | 1 | - |
dc.citation.title | International journal of molecular medicine | - |
dc.citation.volume | 51 | - |
dc.type.docType | Review | - |
dc.publisher.location | 그리이스 | - |
dc.subject.keywordAuthor | anticancer therapy | - |
dc.subject.keywordAuthor | drug resistance | - |
dc.subject.keywordAuthor | exosomes | - |
dc.subject.keywordAuthor | hepatocellular carcinoma | - |
dc.subject.keywordAuthor | miR335 | - |
dc.subject.keywordAuthor | tumor necrosis factor‑related apoptosis‑inducing ligand | - |
dc.subject.keywordPlus | APOPTOSIS-INDUCING LIGAND | - |
dc.subject.keywordPlus | MESENCHYMAL STEM-CELL | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | EXTRACELLULAR VESICLES | - |
dc.subject.keywordPlus | CANCER-CELLS | - |
dc.subject.keywordPlus | GENE-THERAPY | - |
dc.subject.keywordPlus | TUMORICIDAL ACTIVITY | - |
dc.subject.keywordPlus | MONOCLONAL-ANTIBODY | - |
dc.subject.keywordPlus | DEATH RECEPTORS | - |
dc.subject.keywordPlus | CROSS-LINKING | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.